Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alex G. Cuenca is active.

Publication


Featured researches published by Alex G. Cuenca.


Journal of Experimental Medicine | 2011

A genomic storm in critically injured humans

Wenzhong Xiao; Michael Mindrinos; Junhee Seok; Joseph Cuschieri; Alex G. Cuenca; Hong Gao; Douglas L. Hayden; Laura Hennessy; Ernest E. Moore; Joseph P. Minei; Paul E. Bankey; Jeffrey L. Johnson; Jason L. Sperry; Avery B. Nathens; Timothy R. Billiar; Michael A. West; Bernard H. Brownstein; Philip H. Mason; Henry V. Baker; Celeste C. Finnerty; Marc G. Jeschke; M. Cecilia Lopez; Matthew B. Klein; Richard L. Gamelli; Nicole S. Gibran; Brett D. Arnoldo; Weihong Xu; Yuping Zhang; Steven E. Calvano; Grace P. McDonald-Smith

Critical injury in humans induces a genomic storm with simultaneous changes in expression of innate and adaptive immunity genes.


Cancer | 2006

Emerging implications of nanotechnology on cancer diagnostics and therapeutics

Alex G. Cuenca; Huabei Jiang; Steven N. Hochwald; Matthew J. Delano; William G. Cance; Stephen R. Grobmyer

Nanotechnology is multidisciplinary field that involves the design and engineering of objects <500 nanometers (nm) in size. The National Cancer Institute has recognized that nanotechnology offers an extraordinary, paradigm‐changing opportunity to make significant advances in cancer diagnosis and treatment. In the last several decades, nanotechnology has been studied and developed primarily for use in novel drug‐delivery systems (e.g. liposomes, gelatin nanoparticles, micelles). A recent explosion in engineering and technology has led to 1) the development of many new nanoscale platforms, including quantum dots, nanoshells, gold nanoparticles, paramagnetic nanoparticles, and carbon nanotubes, and 2) improvements in traditional, lipid‐based nanoscale platforms. The emerging implications of these platforms for advances in cancer diagnostics and therapeutics form the basis of this review. A widespread understanding of these new technologies is important, because they currently are being integrated into the clinical practice of oncology. Cancer 2006.


Immunity | 2003

A Critical Role for Stat3 Signaling in Immune Tolerance

Fengdong Cheng; Hongwei Wang; Alex G. Cuenca; Mei Huang; Tomar Ghansah; Jason Brayer; William G. Kerr; Kiyoshi Takeda; Shizuo Akira; Stephen P. Schoenberger; Hua Yu; Richard Jove; Eduardo M. Sotomayor

Antigen-presenting cells (APCs) can induce T cell activation as well as T cell tolerance. The molecular mechanisms by which APCs regulate this critical decision of the immune system are not well understood. Here we show that Stat3 signaling plays a critical role in the induction of antigen-specific T cell tolerance. Targeted disruption of Stat3 signaling in APCs resulted in priming of antigen-specific CD4(+) T cells in response to an otherwise tolerogenic stimulus in vivo. Furthermore, APCs devoid of Stat3 effectively break antigen-specific T cell anergy in vitro. Conversely, increased Stat3 activity in APCs led to impaired antigen-specific T cell responses. Stat3 signaling provides, therefore, a novel molecular target for manipulation of immune activation/tolerance, a central decision with profound implications in autoimmunity, transplantation, and cancer immunotherapy.


Journal of Trauma-injury Infection and Critical Care | 2012

Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care

Lori F. Gentile; Alex G. Cuenca; Philip A. Efron; Darwin N. Ang; Azra Bihorac; Bruce A. McKinley; Lyle L. Moldawer; Frederick A. Moore

ABSTRACT Surgical intensive care unit (ICU) stay of longer than 10 days is often described by the experienced intensivist as a “complicated clinical course” and is frequently attributed to persistent immune dysfunction. “Systemic inflammatory response syndrome” (SIRS) followed by “compensatory anti-inflammatory response syndrome” (CARS) is a conceptual framework to explain the immunologic trajectory that ICU patients with severe sepsis, trauma, or emergency surgery for abdominal infection often traverse, but the causes, mechanisms, and reasons for persistent immune dysfunction remain unexplained. Often involving multiple-organ failure (MOF) and death, improvements in surgical intensive care have altered its incidence, phenotype, and frequency and have increased the number of patients who survive initial sepsis or surgical events and progress to a persistent inflammation, immunosuppression, and catabolism syndrome (PICS). Often observed, but rarely reversible, these patients may survive to transfer to a long-term care facility only to return to the ICU, but rarely to self-sufficiency. We propose that PICS is the dominant pathophysiology and phenotype that has replaced late MOF and prolongs surgical ICU stay, usually with poor outcome. This review details the evolving epidemiology of MOF, the clinical presentation of PICS, and our understanding of how persistent inflammation and immunosuppression define the pathobiology of prolonged intensive care. Therapy for PICS will involve innovative interventions for immune system rebalance and nutritional support to regain physical function and well-being.


Molecular Medicine | 2011

A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma.

Alex G. Cuenca; Matthew J. Delano; Kindra M. Kelly-Scumpia; Claudia Moreno; Philip O. Scumpia; Drake LaFace; Paul G. Heyworth; Philip A. Efron; Lyle L. Moldawer

Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of immature myeloid cells whose numbers dramatically increase in chronic and acute inflammatory diseases, including cancer, autoimmune disease, trauma, burns and sepsis. Studied originally in cancer, these cells are potently immunosuppressive, particularly in their ability to suppress antigen-specific CD8+ and CD4+ T-cell activation through multiple mechanisms, including depletion of extracellular arginine, nitrosylation of regulatory proteins, and secretion of interleukin 10, prostaglandins and other immunosuppressive mediators. However, additional properties of these cells, including increased reactive oxygen species and inflammatory cytokine production, as well as their universal expansion in nearly all inflammatory conditions, suggest that MDSCs may be more of a normal component of the inflammatory response (“emergency myelopoiesis”) than simply a pathological response to a growing tumor. Recent evocative data even suggest that the expansion of MDSCs in acute inflammatory processes, such as burns and sepsis, plays a beneficial role in the host by increasing immune surveillance and innate immune responses. Although clinical efforts are currently underway to suppress MDSC numbers and function in cancer to improve antineoplastic responses, such approaches may not be desirable or beneficial in other clinical conditions in which immune surveillance and antimicrobial activities are required.


Journal of Immunology | 2011

Sepsis Induces Early Alterations in Innate Immunity That Impact Mortality to Secondary Infection

Matthew J. Delano; Terri C. Thayer; Sonia Gabrilovich; Kindra M. Kelly-Scumpia; Robert D. Winfield; Philip O. Scumpia; Alex G. Cuenca; Elizabeth A. Warner; Shannon M. Wallet; Mark A. Wallet; Kerri O'Malley; Reuben Ramphal; Michael Clare-Salzer; Philip A. Efron; Clayton E. Mathews; Lyle L. Moldawer

Sepsis, the systemic inflammatory response to microbial infection, induces changes in both innate and adaptive immunity that presumably lead to increased susceptibility to secondary infections, multiorgan failure, and death. Using a model of murine polymicrobial sepsis whose severity approximates human sepsis, we examined outcomes and defined requirements for survival after secondary Pseudomonas aeruginosa pneumonia or disseminated Listeria monocytogenes infection. We demonstrate that early after sepsis neutrophil numbers and function are decreased, whereas monocyte recruitment through the CCR2/MCP-1 pathway and function are enhanced. Consequently, lethality to Pseudomonas pneumonia is increased early but not late after induction of sepsis. In contrast, lethality to listeriosis, whose eradication is dependent upon monocyte/macrophage phagocytosis, is actually decreased both early and late after sepsis. Adaptive immunity plays little role in these secondary infectious responses. This study demonstrates that sepsis promotes selective early, impaired innate immune responses, primarily in neutrophils, that lead to a pathogen-specific, increased susceptibility to secondary infections.


Journal of Immunology | 2010

Cutting Edge: Bacterial Infection Induces Hematopoietic Stem and Progenitor Cell Expansion in the Absence of TLR Signaling

Philip O. Scumpia; Kindra M. Kelly-Scumpia; Matthew J. Delano; Jason S. Weinstein; Alex G. Cuenca; Samer Z. Al-Quran; Ian M. Bovio; Shizuo Akira; Yutaro Kumagai; Lyle L. Moldawer

Bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs) can be activated by type I IFNs, TLR agonists, viruses, and bacteria to increase hematopoiesis. In this study, we report that endotoxin treatment in vivo induces TLR4, MyD88, and Toll/IL-1 resistance domain-containing adaptor-inducing IFN-β (TRIF)-dependent expansion of BM HSPCs. Bacterial infection by Staphylococcus aureus or cecal ligation and puncture also induces HSPC expansion, but MyD88, TRIF, type I IFN, cytokine, PG, or oxidative stress pathways are not required for their expansion. S. aureus-induced HSPC expansion in MyD88−/−TRIF−/− mice is also normal, but is associated with BM remodeling as granulocyte stores are released peripherally. Importantly, reduction in BM cellularity alone can reproduce HSPC expansion. These data show in vivo HSPC responses to bacterial infection are complex and not absolutely dependent upon key inflammatory signaling pathways.


Journal of Experimental Medicine | 2011

B cells enhance early innate immune responses during bacterial sepsis

Kindra M. Kelly-Scumpia; Philip O. Scumpia; Jason S. Weinstein; Matthew J. Delano; Alex G. Cuenca; Dina C. Nacionales; James L. Wynn; Pui Y. Lee; Yutaro Kumagai; Philip A. Efron; Shizuo Akira; Clive Wasserfall; Mark A. Atkinson; Lyle L. Moldawer

Type I interferon–responsive B cells provide early protection against bacterial sepsis.


Journal of Experimental Medicine | 2010

Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10

Kindra M. Kelly-Scumpia; Philip O. Scumpia; Matthew J. Delano; Jason S. Weinstein; Alex G. Cuenca; James L. Wynn; Lyle L. Moldawer

Type I interferon (IFN) α/β is critical for host defense. During endotoxicosis or highly lethal bacterial infections where systemic inflammation predominates, mice deficient in IFN-α/β receptor (IFNAR) display decreased systemic inflammation and improved outcome. However, human sepsis mortality often occurs during a prolonged period of immunosuppression and not from exaggerated inflammation. We used a low lethality cecal ligation and puncture (CLP) model of sepsis to determine the role of type I IFNs in host defense during sepsis. Despite increased endotoxin resistance, IFNAR−/− and chimeric mice lacking IFNAR in hematopoietic cells display increased mortality to CLP. This was not associated with an altered early systemic inflammatory response, except for decreased CXCL10 production. IFNAR−/− mice display persistently elevated peritoneal bacterial counts compared with wild-type mice, reduced peritoneal neutrophil recruitment, and recruitment of neutrophils with poor phagocytic function despite normal to enhanced adaptive immune function during sepsis. Importantly, CXCL10 treatment of IFNAR−/− mice improves survival and decreases peritoneal bacterial loads, and CXCL10 increases mouse and human neutrophil phagocytosis. Using a low lethality sepsis model, we identify a critical role of type I IFN–dependent CXCL10 in host defense during polymicrobial sepsis by increasing neutrophil recruitment and function.


Journal of Immunology | 2011

Neutrophil Mobilization from the Bone Marrow during Polymicrobial Sepsis Is Dependent on CXCL12 Signaling

Matthew J. Delano; Kindra M. Kelly-Scumpia; Terri C. Thayer; Robert D. Winfield; Philip O. Scumpia; Alex G. Cuenca; Phillips B. Harrington; Kerri O'Malley; Elizabeth A. Warner; Sonia Gabrilovich; Clayton E. Mathews; Drake LaFace; Paul G. Heyworth; Reuben Ramphal; Robert M. Strieter; Lyle L. Moldawer; Philip A. Efron

Neutrophils are essential for successful host eradication of bacterial pathogens and for survival to polymicrobial sepsis. During inflammation, the bone marrow provides a large reserve of neutrophils that are released into the peripheral circulation where they traverse to sites of infection. Although neutrophils are essential for survival, few studies have investigated the mechanisms responsible for neutrophil mobilization from the bone marrow during polymicrobial sepsis. Using a cecal ligation and puncture model of polymicrobial sepsis, we demonstrated that neutrophil mobilization from the bone marrow is not dependent on TLR4, MyD88, TRIF, IFNARα/β, or CXCR2 pathway signaling during sepsis. In contrast, we observed that bone marrow CXCL12 mRNA abundance and specific CXCL12 levels are sharply reduced, whereas splenic CXCR4 mRNA and cell surface expression are increased during sepsis. Blocking CXCL12 activity significantly reduced blood neutrophilia by inhibiting bone marrow release of granulocytes during sepsis. However, CXCL12 inhibition had no impact on the expansion of bone marrow neutrophil precursors and hematopoietic progenitors. Bone marrow neutrophil retention by CXCL12 blockade prevented blood neutrophilia, inhibited peritoneal neutrophil accumulation, allowed significant peritoneal bacterial invasion, and increased polymicrobial sepsis mortality. We concluded that changes in the pattern of CXCL12 signaling during sepsis are essential for neutrophil bone marrow mobilization and host survival but have little impact on bone marrow granulopoiesis.

Collaboration


Dive into the Alex G. Cuenca's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge